Fedratinib, a newly approved treatment for patients with myeloproliferative neoplasm-associated myelofibrosis |
|
From leeches to interferon: should cytoreduction be prescribed for all patients with polycythemia vera? |
|
Functional implication of the Lnk adaptator protein in normal and pathological megakaryopoiesis. |
|
Identification of JAK2 mutations in canine primary polycythemia. |
|
Impact of hydroxycarbamide and interferon-α on red cell adhesion and membrane protein expression in polycythemia vera. |
|
The impact of JAK2 and MPL mutations on diagnosis and prognosis of splanchnic vein thrombosis: a report on 241 cases |
|
Impact of ruxolitinib on the natural history of primary myelofibrosis: a comparison of the DIPSS and the COMFORT-2 cohorts. |
|
Implication fonctionnelle de la protéine adaptatrice Lnk dans les cellules normales et pathologiques du lignage mégacaryocytaire |
|
Interferon alfa therapy in CALR-mutated essential thrombocythemia. |
|
Is life expectancy of polycythemia vera patients clearly different from that of the general population? |
|
Is there a role for the use of IFN-α in primary myelofibrosis? |
|
Is there consensus on consensus? |
|
The JAK2 V617F mutation identifies a subgroup of MDS patients with isolated deletion 5q and a proliferative bone marrow |
|
Live and let (MPN cells) die! |
|
Long-term follow-up of JAK2 exon 12 polycythemia vera: a French Intergroup of Myeloproliferative Neoplasms (FIM) study |
|
Long-term incidence of hematological evolution in three French prospective studies of hydroxyurea and pipobroman in polycythemia vera and essential thrombocythemia. |
|
Lu/BCAM-mediated cell adhesion as biological marker of JAK2V617F activity in erythrocytes of polycythemia vera patients. |
|
Mécanisme d'action de l'interferon-alpha dans les néoplasies myeloproliferatives : cellules souches et oligoclonalité |
|
Molecular and clinical features of the myeloproliferative neoplasm associated with JAK2 exon 12 mutations. |
|
Mutations in exon 12 of JAK2 are mainly found in JAK2 V617F-negative polycythaemia vera patients. |
|
Myeloproliferative neoplasms and inflammation: whether to target the malignant clone or the inflammatory process or both |
|
Néoplasies myéloprolifératives et thromboses : épidémiologie et identification des facteurs de risque |
|
New mutations of MPL in primitive myelofibrosis: only the MPL W515 mutations promote a G1/S-phase transition |
|
NF-kappaB constitutes a potential therapeutic target in high-risk myelodysplastic syndrome |
|
PEG-IFN-alpha-2a therapy in patients with myelofibrosis: a study of the French Groupe d'Etudes des Myelofibroses (GEM) and France Intergroupe des syndromes Myéloprolifératifs (FIM) |
|
Pegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera |
|
Philadelphia chromosome-negative chronic myeloproliferative neoplasms: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up |
|
Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet. |
|
Proto-oncogene c-mpl is involved in spontaneous megakaryocytopoiesis in myeloproliferative disorders |
|
Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin |
|
RBC-transfusion guidelines update |
|
LE RECEPTEUR DE LA THROMBOPOIETINE : NOUVELLES ISOFORMES HUMAINES ET EXPRESSION DANS LA THROMBOCYTEMIE ESSENTIELLE |
|
Relevance of the criteria commonly used to diagnose myeloproliferative disorder in patients with splanchnic vein thrombosis |
|
The renaissance of interferon therapy for the treatment of myeloid malignancies |
|
Revised response criteria for polycythemia vera and essential thrombocythemia: an ELN and IWG-MRT consensus project. |
|
Role of JAK2 V617F mutation detection in Budd-Chiari syndrome and portal vein thrombosis associated to myeloproliferative disease. |
|
The role of LNK/SH2B3 genetic alterations in myeloproliferative neoplasms and other hematological disorders |
|
The role of sexuality symptoms in myeloproliferative neoplasm symptom burden and quality of life: An analysis by the MPN QOL International Study Group |
|
Ruxolitinib reduces JAK2 p.V617F allele burden in patients with polycythemia vera enrolled in the RESPONSE study. |
|
Selective testing for calreticulin gene mutations in patients with splanchnic vein thrombosis: A prospective cohort study. |
|
SIMPLIFY-1: A Phase III Randomized Trial of Momelotinib Versus Ruxolitinib in Janus Kinase Inhibitor-Naïve Patients With Myelofibrosis. |
|
Single-cell analysis reveals selection of TP53-mutated clones after MDM2 inhibition |
|
Social Media and Myeloproliferative Neoplasms (MPN): Analysis of Advanced Metrics From the First Year of a New Twitter Community: #MPNSM. |
|
SOCS3 inhibits TPO-stimulated, but not spontaneous, megakaryocytic growth in primary myelofibrosis. |
|
Study of innate immunity in Myelodysplastic syndromes. |
|
Symptom burden profile in myelofibrosis patients with thrombocytopenia: Lessons and unmet needs. |
|
Symptomatic Profiles of Patients With Polycythemia Vera: Implications of Inadequately Controlled Disease. |
|
TET2 gene sequencing may be helpful for myeloproliferative neoplasm diagnosis |
|
Treatment of essential thrombocythemia in Europe: a prospective long-term observational study of 3649 high-risk patients in the Evaluation of Anagrelide Efficacy and Long-term Safety study. |
|
Treatment of polycythemia vera with hydroxyurea and pipobroman: final results of a randomized trial initiated in 1980. |
|
Treatment of progression of Philadelphia-negative myeloproliferative neoplasms to myelodysplastic syndrome or acute myeloid leukemia by azacitidine: a report on 54 cases on the behalf of the Groupe Francophone des Myelodysplasies (GFM). |
|
Treatment strategies in essential thrombocythemia. A critical appraisal of various experiences in different centers |
|
Unraveling the genetic underpinnings of myeloproliferative neoplasms and understanding their effect on disease course and response to therapy: proceedings from the 6th International Post-ASH Symposium |
|
The use of erythropoiesis-stimulating agents with ruxolitinib in patients with myelofibrosis in COMFORT-II: an open-label, phase 3 study assessing efficacy and safety of ruxolitinib versus best available therapy in the treatment of myelofibrosis |
|
Use of the 46/1 haplotype to model JAK2(V617F) clonal architecture in PV patients: clonal evolution and impact of IFNα treatment. |
|
V617F mutation in JAK2 is associated with poorer survival in idiopathic myelofibrosis. |
|
Value of cytogenetic abnormalities in post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a study of the MYSEC project. |
|
What are RBC-transfusion-dependence and -independence? |
|
Which patients with myelofibrosis should receive ruxolitinib therapy? ELN-SIE evidence-based recommendations. |
|